Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Sventrend Jun. 8 at 8:09 PM

$CAPR NS will submit their response as late as possible to give CAPR as short of a time as possible to prepare their remarks

0 · Reply

ezimon Jun. 8 at 8:05 PM

$CAPR A lot of noise: Are 8th, 11th, 17th and FDA approval the only dates that mater, of did I miss anything?

0 · Reply

dnfrs Jun. 8 at 7:51 PM

$CAPR Fintel says Institutional ownership now over 62% "Institutional Ownership and Shareholders. Capricor Therapeutics, Inc. (US:CAPR) has 186 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 36,126,494 shares. Largest shareholders include Suvretta Capital Management, Llc, BlackRock, Inc., Tang Capital Management Llc, Vanguard Group Inc, State Street Corp, Vanguard Capital Management Llc, Ra Capital Management, L.p., Geode Capital Management, Llc, Susquehanna International Group, Llp, and Goldman Sachs Group Inc ." And yes, I did notice Goldman Sachs Group!

0 · Reply

BioResearcher Jun. 8 at 7:45 PM

$CAPR NS is fully in charge ! NS is choking this company,

2 · Reply

Hoganknowsbest Jun. 8 at 7:42 PM

$CAPR fuckin bullshit.

0 · Reply

StillFishing Jun. 8 at 7:25 PM

$CAPR Buy at $26 if you like profit!

0 · Reply

hegdaom Jun. 8 at 7:14 PM

$CAPR

0 · Reply

NoSwagger Jun. 8 at 7:04 PM

$CAPR @Sawnchey You still out there? Any insight into recent goings-on here at capr?

0 · Reply

e_jens_ Jun. 8 at 6:55 PM

$CAPR the slow bleeds are the worst. But has any data changed? Does NS have any weight to their argument? We all know the answers. DCA and accumulate. August is around the corner.

0 · Reply

dnfrs Jun. 8 at 6:39 PM

$CAPR Capricor is presenting at both Oppenheimer and Goldman Sachs (on-line) on Wednesday June 10. I would not want to be short!

0 · Reply

Capricor Therapeutics to Present at Upcoming Investor Conferences

2026-05-15T02:55:10.000Z - 24 days ago

Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

May 12, 2026, 4:30 PM EDT - 26 days ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 26 days ago

Capricor Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 26 days ago

Capricor Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 27 days ago

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-08T18:58:25.000Z - 4 weeks ago

Capricor files suit against NS Pharma over Deramiocel distribution deal

May 4, 2026, 4:05 PM EDT - 5 weeks ago

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Capricor Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Capricor Therapeutics Proxy statement: Proxy filing

2026-03-20T12:45:14.000Z - 2 months ago

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

2026-03-13T18:35:53.000Z - 3 months ago

Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T16:01:07.000Z - 3 months ago

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

2026-03-13T12:27:39.000Z - 3 months ago

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

2026-03-13T12:02:13.000Z - 3 months ago

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings release: Q4 2025

2026-03-12T20:16:10.000Z - 3 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

Mar 12, 2026, 4:01 PM EDT - 3 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-03-12T13:15:17.000Z - 3 months ago

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Mar 12, 2026, 9:00 AM EDT - 3 months ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

2026-03-10T13:38:59.000Z - 3 months ago

Capricor announces establishment of new PDUFA date for dermiocel BLA

Mar 10, 2026, 9:25 AM EDT - 3 months ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

2026-01-20T14:25:31.000Z - 4 months ago

Capricor expects to submit updates to BLA in February 2026

Dec 17, 2025, 1:00 PM EST - 6 months ago

Capricor Therapeutics Transcript: Study Result

2025-12-15T13:20:28.000Z - 6 months ago

Capricor Therapeutics price target raised to $50 from $21 at B. Riley

2025-12-10T11:51:19.000Z - 6 months ago

Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler

2025-12-08T13:46:18.000Z - 6 months ago

Capricor Therapeutics management to meet with Oppenheimer

Dec 4, 2025, 4:01 PM EST - 6 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 11:30 AM EST - 6 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 6 months ago

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 6 months ago

Capricor Therapeutics Press release: Status Update

Dec 3, 2025, 8:00 AM EST - 6 months ago

Capricor Therapeutics Slides: Status Update

Dec 3, 2025, 7:44 AM EST - 6 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 10, 2025, 4:30 PM EST - 7 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Capricor Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Capricor Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 9:15 AM EST - 7 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 7 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 13, 2025, 7:00 AM EDT - 8 months ago

Capricor Therapeutics Slides: Corporate Presentation

Oct 3, 2025, 10:45 AM EDT - 8 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Press release: Study Update

Sep 25, 2025, 7:15 AM EDT - 9 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 10, 2025, 8:00 AM EDT - 9 months ago

Capricor Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 9:20 AM EDT - 9 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Capricor Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Capricor Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 10 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 14, 2025, 4:14 PM EDT - 11 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 11, 2025, 4:53 PM EDT - 11 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Transcript: Study Update

Jul 11, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Press release: Study Update

Jul 11, 2025, 6:36 AM EDT - 11 months ago

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:30 AM EDT - 11 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jun 24, 2025, 9:16 AM EDT - 1 year ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 20, 2025, 9:25 AM EDT - 1 year ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Sventrend Jun. 8 at 8:09 PM

$CAPR NS will submit their response as late as possible to give CAPR as short of a time as possible to prepare their remarks

0 · Reply

ezimon Jun. 8 at 8:05 PM

$CAPR A lot of noise: Are 8th, 11th, 17th and FDA approval the only dates that mater, of did I miss anything?

0 · Reply

dnfrs Jun. 8 at 7:51 PM

0 · Reply

BioResearcher Jun. 8 at 7:45 PM

$CAPR NS is fully in charge ! NS is choking this company,

2 · Reply

Hoganknowsbest Jun. 8 at 7:42 PM

$CAPR fuckin bullshit.

0 · Reply

StillFishing Jun. 8 at 7:25 PM

$CAPR Buy at $26 if you like profit!

0 · Reply

hegdaom Jun. 8 at 7:14 PM

$CAPR

0 · Reply

NoSwagger Jun. 8 at 7:04 PM

$CAPR @Sawnchey You still out there? Any insight into recent goings-on here at capr?

0 · Reply

e_jens_ Jun. 8 at 6:55 PM

$CAPR the slow bleeds are the worst. But has any data changed? Does NS have any weight to their argument? We all know the answers. DCA and accumulate. August is around the corner.

0 · Reply

dnfrs Jun. 8 at 6:39 PM

$CAPR Capricor is presenting at both Oppenheimer and Goldman Sachs (on-line) on Wednesday June 10. I would not want to be short!

0 · Reply

NoMonkeyBusiness Jun. 8 at 6:01 PM

$CAPR In theory, NS has until midnight tonight to file their response online. At 12:01AM, we will be able to tell what happened.

2 · Reply

ys95 Jun. 8 at 5:54 PM

$CAPR where are our lawyers? When do we hear what happened today. TIA

2 · Reply

td5750581 Jun. 8 at 5:51 PM

$CAPR come on lindaa

0 · Reply

TooHot_toTouch Jun. 8 at 5:45 PM

$CAPR Should we expect a PR about labeling discussions initiation or progress ? Any board members who have been through other labeling discussions?

2 · Reply

TooHot_toTouch Jun. 8 at 5:44 PM

$CAPR I do not see any valid argument or path NS Pharma has other than frustrate and delay. I hope the judge sees right through their BS.

0 · Reply

hegdaom Jun. 8 at 5:08 PM

$CAPR

0 · Reply

hegdaom Jun. 8 at 5:08 PM

$CAPR

0 · Reply

hegdaom Jun. 8 at 5:08 PM

$CAPR

0 · Reply

Galaxy123 Jun. 8 at 5:08 PM

$CAPR no response from NonSense Pharma yet. Let’s see if they request for an extension…

5 · Reply

NoMonkeyBusiness Jun. 8 at 5:01 PM

$CAPR Curious, like many here, I hold both CAPR and IBRX. Given that CAPR has a PDUFA date, would we expect CAPR to have a nice move up BEFORE IBRX? Trying to decide on allocation.

1 · Reply

Parsnip Jun. 8 at 3:50 PM

$CAPR

0 · Reply

Sparky24 Jun. 8 at 3:44 PM

$CAPR Hoping this is the bottom. Slow bleed getting old.

0 · Reply

Market Cap	1.55B
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	639,051
Avg Vol	991,654
Day's Range	N/A - N/A
Shares Out	57.91M
Stochastic %K	4%
Beta	0.39
Analysts	Strong Sell
Price Target	$54.11